Rezolute is currently conducting the following clinical studies:
An Open-Label Multiple-Dose Study of RZ358 in Patients with Congenital Hyperinsulinism. The study is currently enrolling patients. For patients or physicians interested in learning more about the study, please visit the clinicaltrials.gov entry NCT04538989 or visit the EU Clinical Trials Register entry 2016-004186-83 for more about sites in the US, EU and other participating countries.
Rezolute has completed a successful pre-IND meeting with the FDA and IND-enabling toxicology studies in preparation for a Phase 1 study of RZ402 in DME. The exact timing of IND filing and study initiation is currently unknown due to the ongoing COVID-19 pandemic.
Rezolute is committed to ensuring the safety of patients and volunteers who participate in any of our ongoing clinical trials. We strictly follow regulatory requirements to ensure the health and well-being of our participants at all times.